Anti-Dyslipidemic Effects Of Pleurotusostreatus (Oyster Mushroom) In Diet-Induced Hyperlipidemic Mice.
Keywords:
Oyster mushrooms, Pleurotusostratus, dyslipidemia, hyperlipidemiaAbstract
Background: Only a few antidyslipidemic drugs are currently available in clinical practice for the prophylactic control of ischemic stroke and coronary heart diseases. Fungal secondary metabolism remains a veritable repertoire for the discovery of new ones. This study was aimed at evaluating a methanol crude extract of the fungus, Pleurotusostreatus (oyster mushroom), and its fractions for their potential anti-dyslipidemic activities in high fat diet-induced models of dyslipidemia.
Methods: A methanol extract of Pleurotusostratus, obtained by cold maceration, was subjected to phytochemical screenings and triturated in succession into dichloromethane and methanol to obtain non-polar and polar fractions respectively. Each of the extract and the fractions was subjected to antidyslipidemic assay in vivo in mice by measuring their effects on diet-induced hyperlipidemic
mice using plasma Total Cholesterol (TC), Very Low Density Lipoprotein cholesterol (VLDLC), Low Density Lipoprotein cholesterol (LDLC), High Density Lipoprotein cholesterol (HDLC) and triglycerides (TG) concentration changes as biomarkers, 2O/atw€'en 2o and z5mg/Kg
artovastatin being negative (i.e., dyslipidemic) and positive controls respectively.
Results: ANOVA comparison of the test groups mean values of these biomarkers with those of the dyslipidemic control group showed that the crude extract significantly reduced plasma TC (p < o.oz), LDLC (p < o.oooz), TG and VLDLC (p < o.of), and significantly increased HDLC(p < o.of). In addition, the non-polarfraction significantly reduced plasma TG and VLDLC(p < o.oz) and significantly elevated HDLC (p < o.oooz) while the polar fraction had significant reduction effects on the TC and LDLC plasma concentrations(p < o.oz).
Conclusion: The methanol crude extract of Pleurotusostratusde monstrated antidyslipidemic activity, reversing all the biomarkers of dyslipidemia in diet-induced hyperlipidemic mice. The effect on the biomarkers appeared separated, though, with fractionation, the non-polar fraction reversing the TG, VLDLC and HDLC and the polar fraction the TC and LDLC parameters. Pleurotusoestratus could
therefore be explored for the discovery of new anti-dyslipidemic drugs.
References
Davidson M (2008). A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. The American Journal of Cardiology 102(12)19L-21L.
Dhaliya SA, SuryaAS, DawnVT, Betty C, Arun K and Sunil C (20i3). A review of hyperlipidemia and medicinal plants. International Journal
of Applied Pharmaceutical Sciences and Biological Sciences2(4); 219-237.
Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton JR, Hart RG (2006). Primary prevention of ischemic stroke: A guideline from the American heart association/American stroke association stroke counciI : Cosponsored by the atherosclerotic peripheral vascuIar disease interdisciplinary working group; cardiovascular nursing council; clinical cardiology
council; nutrition, physical activity, and metabolism council; and the quality of care and outcomes research interdisciplinary working group: The American academy of neurology affirms the value of this guideline. Stroke; A Journal of Cerebral Circulation37 (6); 1583-1633.
Anyfantakis ZA, Baron G, Aubry P, Himbert D, Feldman LJ, Juliard JM, Ricard-Hibon A, Burnod A, Cokkinos DV and Steg PG (2009). Acute
coronary angiographic findings in survivors of out-of-hospital cardiac arrest. American Heart Journal157(2); 312-318.
Tziomalos K, AthyrosVG, Karagiannis A and Mikhailidis DP(2009). Dyslipidemia as a risk factor for ischemic stroke. Current topics in medicinal chemistry9(14);1291-1297.
Pollex RL, Joy TR and Hegele RA (2008). Emerging AntidyslipidemicDrugs. Expert Opinion on Emerging Drugs13(2); 363-381.
Sashidhara KV, Kumar A, Kumar M, Srivastava A and Puri A (2010). Synthesis and antihyperlipidemic activity of novel coumarin bisindole derivatives. Bioorganic and Medicinal Chemistry Letters20(22); 6504-6507.
Stossel TP (2008). The discovery of statins. Cell134(6); 903-905. 9. Endo A (2010). A historical perspective on the discovery of statins. Proceedings of the Japan Academy, Series B86(5); 484-493.
Liang B, Guo Z, Xie F, Zhao A (2013). Antihyperglycemic and antihyperlipidemic activities of aqueous extract of Hericiumerinaceus in experimental diabetic rats. BMC Complementary and Alternative Medicine13(1); 253-260.
de Miranda AM, Ribeiro GM, Cunha AC, Silva LS, dos Santos RC, Pedrosa ML and Silva ME (2014). Hypolipidemic effect of the edible mushroom Agaricusblazei in rats subjected to a hypercholesterolemic diet. Journal of Physiology and Biochemistry70(1); 215-224.
Yadav S, Satapathy T, Roy A and Prasad P (2014). Antihyperlipidemic potential of herbals. Journal of Applied Pharmaceutical Research2(1);
-17.
ChoiD, Piao Y, Yu SJ, LeeYW, Lim DH, Chang YC, Park SS, Lee MK, ChaWS, You DS and Cho H (2016). Antihyperglycemic and antioxidant
activities of polysaccharide produced from Pleurotus ferulae. Korean Journal of Chemical Engineering33(6);1872-1882.
BobekP and Galbavý Š (1999). Hypocholesterolemic and antiatherogenic effect of oyster mushroom (Pleurotusostreatus) in rabbits. Molecular Nutrition and Food Research43(5); 339-342.
Schneider I, Kressel G, Meyer A, Krings U, Berger RG and Hahn A (2011). Lipid lowering effects of oyster mushroom (Pleurotusostreatus) in humans. Journal of Functional Foods3(1);17-24.
GuYH, Sivam G (2006). Cytotoxic effect of oyster mushroom Pleurotusostreatus on human androgen-independent prostate cancer PC-3 cells. Journal of medicinal food9(2);196-204.
Kim JH, Kim SJ, Park HR, Choi JI, Ju YC, Nam KC, Lee SC (2009). The different antioxidant and anticancer activities depending on the color of oyster mushrooms. Journal of Medicinal Plants Research3(12); 1016-1020.
Ganeshpurkar A, Bhadoriya SS, Pardhi P, Jain AP and Rai G (2011). In vitro prevention of cataract by Oyster Mushroom Pleurotusflorida extract on isolated goat eye lens. Indian journal of pharmacology43(6); 667-.670
Rosenson RS (2005). Low HDL-C: a secondary target of dyslipidemia therapy. The American Journal of Medicine118(10);1067-1077.
Trease GE and Evans WC (2002). Pharmacognosy. 15th Ed. London, Saunders Publishers, Pp. 42–44, 221-229.
Edeoga HO, Okwu DE, Mbaeble BO (2005). Phytochemical Constituents of Some Nigerian Medicinal Plants. African Journal of Biotechnology 4(7); 685-688.
Matos SL, Paula HD, Pedrosa ML, Santos RCD, Oliveira ELD, Chianca Júnior DAand Silva ME (2005). Dietary models for inducing hypercholesterolemia in rats. Brazilian Archives of Biology and Technology48(2); 203-209.
Bacolo G, David H(1973). Quantitative determination of serum triglycerides by the use of enzymes. Clinical Chemistry 19; 476-482.
Allain CC, PooLS, Chan CSG, Richmond W, Fu PC (1974). Enzymatic determination of total serum Cholesterol. Clinical Chemistry 20; 470-475.
Friedewald W T, Levy RI, Fredrickson DS (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18(6); 499–502.
Joris I, Zand T, Nunnari JJ, Krolikwoski FJ, Majno G (1983). Studies on the pathogenesis of atherosclerosis I; adhesion and emigration of
mononuclear cells in the aorta of hypercholesterolemic rats. American Journal of Pathology 113; 341-358.
Rosenthal MD and Glew RH(2009). Medical Biochemistry, Human metabolism in health and disease. John Wiley, Hoboken, NJ. USA. Pp
-270.
